No headlines found.
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
Globe Newswire (Fri, 14-Aug 4:15 PM ET)
Globe Newswire (Thu, 13-Aug 7:30 AM ET)
Globe Newswire (Thu, 6-Aug 7:30 AM ET)
Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.
Cerenome trades on the NASDAQ stock market under the symbol CNSY.
As of August 14, 2026, CNSY stock price declined to $3.68 with 86,042 million shares trading.
CNSY has a market cap of $25.33 million. This is considered a Sub-Micro Cap stock.
Last quarter Cerenome reported $1 million in Revenue and -$1.05 earnings per share. This beat revenue expectation by $58,800 and missed earnings estimates by -$.17.
The top ETF exchange traded funds that CNSY belongs to (by Net Assets): IWC.
CNSY support price is $3.49 and resistance is $3.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNSY shares will trade within this expected range on the day.